Lassa Fever (Lassa Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 65 Published: May 31, 2022 Report Code: GDGMDHC22167IDB

Lassa Fever (Lassa Hemorrhagic Fever) pipeline market research report provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects.

Key Targets in the Lassa Fever Pipeline Market

The key targets in the Lassa fever pipeline market are Glycoprotein and RNA Directed RNA Polymerase.

Key MoA Types in the Lassa Fever Pipeline Market

The key MoA types in the Lassa fever pipeline market are RNA Directed RNA Polymerase Inhibitor.

Key RoA Types in the Lassa Fever Pipeline Market

The key RoA types in the Lassa fever pipeline market are intramuscular, oral, intravenous, intradermal, and subcutaneous. Intramuscular has the highest pipeline products in the Lassa fever pipeline market.

Lassa Fever Pipeline Market, by RoA

Lassa Fever Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Lassa Fever Pipeline Market

The key molecule types in the Lassa fever pipeline market are recombinant vector vaccine, small molecule, vaccine, DNA vaccine, live attenuated vaccine, monoclonal antibody, and mRNA Vaccine. Recombinant Vector Vaccine has the highest pipeline products.

Lassa Fever Pipeline Market, by Molecule Types

Lassa Fever Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Lassa Fever Pipeline Market

The key companies in the Lassa fever pipeline market are Helix Biogen Institute, Emergent BioSolutions Inc, Kineta Inc, Curevac NV, FUJIFILM Toyama Chemical Co Ltd, GeoVax Labs Inc, and Globavir Biosciences Inc. Helix Biogen Institute has the highest pipeline products.

Lassa Fever Pipeline Market, by Companies

Lassa Fever Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Glycoprotein and RNA Directed RNA Polymerase
Key MoA types RNA Directed RNA Polymerase Inhibitor
Key RoA types Intramuscular, Oral, Intravenous, Intradermal, and Subcutaneous
Key molecule types Recombinant Vector Vaccine, Small Molecule, Vaccine, DNA Vaccine, Live Attenuated Vaccine, Monoclonal Antibody, and mRNA Vaccine
Key companies Helix Biogen Institute, Emergent BioSolutions Inc, Kineta Inc, Curevac NV, FUJIFILM Toyama Chemical Co Ltd, GeoVax Labs Inc, and Globavir Biosciences Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • Curevac NV

    Emergent BioSolutions Inc

    FUJIFILM Toyama Chemical Co Ltd

    GeoVax Labs Inc

    Globavir Biosciences Inc

    Helix Biogen Institute

    ImmunityBio Inc

    Inovio Pharmaceuticals Inc

    Kineta Inc

    Themis Bioscience GmbH

    Tonix Pharmaceuticals Holding Corp

    Zalgen Labs LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lassa Fever (Lassa Hemorrhagic Fever) – Overview

Lassa Fever (Lassa Hemorrhagic Fever) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Lassa Fever (Lassa Hemorrhagic Fever) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lassa Fever (Lassa Hemorrhagic Fever) – Companies Involved in Therapeutics Development

Curevac NV

Emergent BioSolutions Inc

FUJIFILM Toyama Chemical Co Ltd

GeoVax Labs Inc

Globavir Biosciences Inc

Helix Biogen Institute

ImmunityBio Inc

Inovio Pharmaceuticals Inc

Kineta Inc

Themis Bioscience GmbH

Tonix Pharmaceuticals Holding Corp

Zalgen Labs LLC

Lassa Fever (Lassa Hemorrhagic Fever) – Drug Profiles

(Ebola + Lassa Fever + Marburg) vaccine – Drug Profile

Product Description

Mechanism Of Action

(Lassa fever + rabies) vaccine – Drug Profile

Product Description

Mechanism Of Action

arevirumab-3 – Drug Profile

Product Description

Mechanism Of Action

History of Events

favipiravir – Drug Profile

Product Description

Mechanism Of Action

History of Events

GBV-006 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GEOLM-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

hemorrhagic fever vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

INO-4500 – Drug Profile

Product Description

Mechanism Of Action

History of Events

lassa fever vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

lassa fever vaccine – Drug Profile

Product Description

Mechanism Of Action

lassa fever vaccine – Drug Profile

Product Description

Mechanism Of Action

lassa fever vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

lassa fever vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

Lassa fever vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

lassa fever vaccine – Drug Profile

Product Description

Mechanism Of Action

lassa fever vaccine 1 – Drug Profile

Product Description

Mechanism Of Action

lassa fever vaccine 2 – Drug Profile

Product Description

Mechanism Of Action

lassa vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

LHF-535 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ML-29 – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Lassa Fever – Drug Profile

Product Description

Mechanism Of Action

TNX-3500 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Vaccine for Infectious Diseases and Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Lassa Fever (Lassa Hemorrhagic Fever) – Dormant Projects

Lassa Fever (Lassa Hemorrhagic Fever) – Product Development Milestones

Featured News & Press Releases

Oct 26, 2021: INOVIO completes enrollment of phase 1B clinical trial for its DNA vaccine candidate against Lassa fever, INO-4500, in West Africa

Jul 14, 2021: Batavia successfully uses innovative hip-vax to manufacture IAVI’s lassa fever vaccine candidate for phase I clinical trials

Jun 15, 2021: EDCTP and CEPI Funding moves IAVI’s lassa fever vaccine candidate into advanced clinical development

Feb 23, 2021: INOVIO announces first subject dosed in phase 1B clinical trial for its DNA vaccine against lassa fever, INO-4500, in West Africa

Mar 25, 2020: Kineta presents clinical study results of LHF-535 at the International Conference on Antiviral Research (ICAR)

Oct 30, 2019: Themis Bioscience and CEPI trial Lassa fever vaccine

Aug 06, 2019: Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535

Jul 16, 2019: GeoVax announces upcoming presentation of lassa fever vaccine data

Jul 15, 2019: Kineta secures NIAID grant worth up to $5.8M to evaluate LHF-535 in Arenaviruses

May 23, 2019: Inovio doses patients in Phase I trial of Lassa virus vaccine INO-4500

Dec 11, 2018: Batavia Biosciences Partners with IAVI to Advance Development of Vaccine Against Lassa Fever

Sep 26, 2018: GeoVax awarded $2.4 million from U.S. Department of Defense to advance Lassa Fever Vaccine

Sep 15, 2018: Advanced preclinical development and production of master seed virus of GEO-LM01, a novel MVA-VLP vaccine against Lassa Fever

Sep 05, 2018: Kineta initiates first-in-human clinical trial of LHF-535 a novel therapy for lassa fever

Aug 20, 2018: Emergent and Profectus receive CEPI contract for Lassa virus vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Curevac NV, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Emergent BioSolutions Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by GeoVax Labs Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Globavir Biosciences Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Helix Biogen Institute, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by ImmunityBio Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Inovio Pharmaceuticals Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Kineta Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Themis Bioscience GmbH, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Tonix Pharmaceuticals Holding Corp, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Zalgen Labs LLC, 2022

Lassa Fever (Lassa Hemorrhagic Fever) – Dormant Projects, 2022

List of Figures

List of Figures

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.